<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253526</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000448825</org_study_id>
    <secondary_id>NCI-05-C-0158</secondary_id>
    <secondary_id>NCI-P6503</secondary_id>
    <nct_id>NCT00253526</nct_id>
    <nct_alias>NCT00158392</nct_alias>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer</brief_title>
  <official_title>Phase II Randomized Study of Surgical Resection and Adjuvant Gemcitabine Hydrochloride With Versus Without Bevacizumab in Patients With Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine&#xD;
      hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how&#xD;
      well they work compared to gemcitabine hydrochloride alone in treating patients who are&#xD;
      undergoing surgery for pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the disease-free interval in patients with adenocarcinoma of the pancreas&#xD;
           treated with surgical resection followed by adjuvant gemcitabine hydrochloride with vs&#xD;
           without bevacizumab.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare overall survival in patients treated with these regimens.&#xD;
&#xD;
        -  Evaluate tumor gene expression profiles and levels of tumor angiogenesis markers to&#xD;
           establish prognostic indicators for response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled study.&#xD;
&#xD;
      All patients undergo surgical resection for the pancreatic tumor. Within 4-8 weeks after&#xD;
      surgery, patients are stratified according to projected 2-year survival (≤ 5% vs &gt; 5% and ≤&#xD;
      33% vs &gt; 33%). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and&#xD;
           15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28&#xD;
           days for 6 courses. Patients then receive bevacizumab IV alone every 2 weeks for up to 2&#xD;
           years in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and&#xD;
           15. Treatment repeats every 28 days for 6 courses in the absence of disease progression&#xD;
           or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage I Pancreatic Cancer</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-cytokine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiangiogenesis therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>growth factor antagonist therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>monoclonal antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
          -  No evidence of distant metastasis on laparoscopy&#xD;
&#xD;
          -  No superior mesenteric artery or thrombosed superior mesenteric vein involvement&#xD;
&#xD;
          -  Superior mesenteric vein or portal vein involvement allowed&#xD;
&#xD;
          -  Evidence of a pancreatic mass by radiographic or endoscopic examination&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 2,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,250/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C virus negative&#xD;
&#xD;
          -  No history of hepatic cirrhosis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Proteinuria negative or trace by urinalysis OR&#xD;
&#xD;
          -  Protein &lt; 1 g on 24 hr urine collection&#xD;
&#xD;
          -  No active gross hematuria&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe congestive heart failure&#xD;
&#xD;
          -  No active ischemic heart disease&#xD;
&#xD;
          -  No ischemic changes on a cardiac thallium stress test&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure ≤ 150/100 mm Hg despite&#xD;
             antihypertensive therapy)&#xD;
&#xD;
          -  No active coagulation disorder&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No active gross hemoptysis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during the adjuvant therapy part of&#xD;
             trial&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No wound healing problem from recent invasive procedure&#xD;
&#xD;
          -  No significant history of medical illness that would preclude patient from undergoing&#xD;
             an operative procedure&#xD;
&#xD;
          -  No other malignancy requiring systemic therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior immunotherapy for pancreatic cancer&#xD;
&#xD;
          -  No prior bevacizumab&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy for pancreatic cancer&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Recovered from prior hormonal therapy for pancreatic cancer&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy for pancreatic cancer&#xD;
&#xD;
          -  No prior radiotherapy to the pancreas&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior definitive resection of the primary pancreatic tumor&#xD;
&#xD;
          -  Prior surgery, other than resection of the primary tumor, allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior systemic therapy for this cancer&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation causing elevated PT or PTT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard E. Royal, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

